Eli Lilly Pauses COVID-19 Antibody Trial

2
>>Follow Matzav On Whatsapp!<<

Enrollment for Eli Lilly’s late-stage trial of its monoclonal antibody treatment is being put on hold over potential safety concerns following a recommendation from U.S. health regulators.

“Safety is of the utmost importance to Lilly,” an Eli Lilly spokesperson told FOX Business in a statement Tuesday. “We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.”

The trial is used to test the safety and efficacy of Eli Lilly’s antibody treatment for hospitalized patients battling  COVID-19, and is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Read more at Fox Business.

{Matzav.com}

2 COMMENTS

  1. Until now doctors told us that it’s a positive thing to have antibodies as it’s a sign that you already had “coronavirus”. (As if people weren’t sick more than once with corona nonsense throughout these months.) Now suddenly they’re treating antibodies? What’s going on?

LEAVE A REPLY

Please enter your comment!
Please enter your name here